# Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

> **NCT00962767** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 168 (actual)

## Conditions studied

- Leukemia, Myelocytic, Acute

## Interventions

- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** ATRA plus 6-MP and MTX

## Key facts

- **NCT ID:** NCT00962767
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2009-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962767, "Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00962767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*